- Home
- TLX vs NEA Comparison
TLX vs NEA Comparison
Compare TLX & NEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLX
- NEA
- Stock Information
- Founded
- TLX 2015
- NEA 2002
- Country
- TLX Australia
- NEA United States
- Employees
- TLX N/A
- NEA N/A
- Industry
- TLX Biotechnology: Pharmaceutical Preparations
- NEA Finance/Investors Services
- Sector
- TLX Health Care
- NEA Finance
- Exchange
- TLX Nasdaq
- NEA Nasdaq
- Market Cap
- TLX 3.6B
- NEA 3.4B
- IPO Year
- TLX N/A
- NEA N/A
- Fundamental
- Price
- TLX $8.95
- NEA $11.45
- Analyst Decision
- TLX Strong Buy
- NEA
- Analyst Count
- TLX 4
- NEA 0
- Target Price
- TLX $21.00
- NEA N/A
- AVG Volume (30 Days)
- TLX 80.2K
- NEA 803.4K
- Earning Date
- TLX 01-01-0001
- NEA 01-01-0001
- Dividend Yield
- TLX N/A
- NEA 4.23%
- EPS Growth
- TLX N/A
- NEA N/A
- EPS
- TLX 0.04
- NEA N/A
- Revenue
- TLX $664,225,558.00
- NEA N/A
- Revenue This Year
- TLX N/A
- NEA N/A
- Revenue Next Year
- TLX N/A
- NEA N/A
- P/E Ratio
- TLX $207.08
- NEA N/A
- Revenue Growth
- TLX 55.35
- NEA N/A
- 52 Week Low
- TLX $8.76
- NEA $9.20
- 52 Week High
- TLX $30.36
- NEA $11.37
- Technical
- Relative Strength Index (RSI)
- TLX 33.79
- NEA 46.34
- Support Level
- TLX $8.76
- NEA $11.49
- Resistance Level
- TLX $9.40
- NEA $11.55
- Average True Range (ATR)
- TLX 0.24
- NEA 0.09
- MACD
- TLX -0.13
- NEA -0.02
- Stochastic Oscillator
- TLX 12.83
- NEA 20.59
About TLX Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
About NEA Nuveen AMT-Free Quality Municipal Income Fund of Beneficial Interest Par Value $.01
Nuveen AMT-Free Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and the alternative minimum tax applicable to individuals, by investing in an actively managed portfolio of tax-exempt municipal securities. The company invest in Transportation, Utilities, Healthcare, Education and Civics, and other sectors, with maximum investment in Transportation.